Stay updated on CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial

Sign up to get notified when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The clinical trial record is displayed, including the study design, pembrolizumab treatment, eligibility criteria, recruitment location, contacts, and outcome measures.
    Difference
    42%
    Check dated 2026-11-07T13:22:06.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-31T14:09:04.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A site-wide NIH announcement banner was added with links to transition updates and a notice that NIH content may use “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T16:22:32.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.
    Difference
    0.2%
    Check dated 2026-10-17T16:18:20.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The site revision identifier changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T16:15:24.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The page remains on a 403 Forbidden error screen, with no visible change to its content or layout.
    Difference
    0.2%
    Check dated 2026-10-03T16:13:26.000Z thumbnail image

Stay in the know with updates to CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CTA and Methylation in NSCLC Response to Pembrolizumab Clinical Trial page.